Roche moves ahead with Phase 3 Parkinson’s study despite mixed trial results
Roche and Prothena said they’re planning to proceed with a Phase 3 study of an experimental Parkinson’s antibody called prasinezumab, even …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
